Immunic, Inc. (10VA)
XFRA 
Summary
10VA Chart
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, North Carolina, including a late-breaking analysis of its lead drug candidate vidofludimus calcium in patients with progressive multiple sclerosis. The late-breaking poster introduced a novel unified endpoint called Confirmed Disability Change, designed to capture both disability worsening and improvement within a single statistical framework.
FTSE 100 Live: Global markets hit record highs, oil prices slide as Iran deal awaited
FTSE 100 up 13 points at 10,505 Asian and US tech stocks drive new global markets to all-time highs Energy prices and govt bonds ease on Iran optimism UK...
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its chief executive officer as the company advances its multiple sclerosis treatment candidate through late-stage development and prepares for potential commercialization. He succeeds Daniel Vitt, who will continue to oversee scientific strategy and portfolio advancement while remaining on the company's board of directors.
Immunic, Inc. (10VA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Immunic, Inc. ever had a stock split?
Immunic, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Daniel Vitt CEO | XFRA Exchange | US4525EP1011 ISIN |
| US Country | 91 Employees | 15 Apr 2019 Last Dividend | 27 Apr 2026 Last Split | 17 Apr 2014 IPO Date |
Overview
Immunic, Inc. is a biotechnology company with a core focus on the development of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Established in 2016 and with operations in both the United States and Germany, Immunic, Inc. dedicates itself to advancing a pipeline of novel treatments that promise a brighter future for patients suffering from these debilitating conditions. By targeting the underlying causes of such diseases, Immunic strives to deliver effective and innovative medical solutions that can improve the quality of life for those affected.
Products and Services
- IMU-838 - This leading drug candidate is currently in Phase 3 clinical trial stages, focusing on the treatment of multiple sclerosis, including both relapsing and progressive types, as well as moderate-to-severe ulcerative colitis. IMU-838 represents Immunic, Inc.'s commitment to addressing auto-immune challenges through selective oral immunology therapies, targeting a critical need in the management of auto-immune and inflammatory diseases.
- IMU-856 - Poised to enter Phase 2 clinical trials, IMU-856 is being developed as a solution for the restoration of intestinal barrier function in patients suffering from a variety of gastrointestinal diseases. These include celiac disease, inflammatory bowel disease, short bowel syndrome, and irritable bowel syndrome with diarrhea, among others. This product focuses on restoring the natural defense mechanisms of the gastrointestinal tract, which is a novel approach to treating these conditions.
- IMU-381 - Still in the preclinical trial phase, IMU-381 is designed to target gastrointestinal diseases, with a focus on a new method of treatment. Although details about its specific action are less advanced than those of IMU-838 and IMU-856, IMU-381 represents Immunic, Inc.'s ongoing efforts to expand its portfolio and tackle a broader range of inflammatory and autoimmune diseases through innovative therapeutic approaches.
